Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 43

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 43
---
 | ​                                                                  | ​ |    — | ​ | ​ | ​ | ​                                                                                                                               | ​ |         — | ​ | ​ |
| Equity compensation plans not approved by security holders | ​ | ​ | ​                                                                    | ​ |         — | ​ | ​ | ​ | ​                                                                  | ​ |    — | ​ | ​ | ​ | ​                                                                                                                               | ​ |         — | ​ | ​ |
| Total                                                      | ​ | ​ | ​                                                                    | ​ | 3,975,965 | ​ | ​ | ​ | ​                                                                  | $ | 3.74 | ​ | ​ | ​ | ​                                                                                                                               | ​ | 3,405,908 | ​ | ​ |

(a) The number of shares subject to outstanding awards under the 2016 Plan represents the total number of issued and outstanding stock options and restricted stock units. (b) The weighted average exercise price reported in this column does not take into account outstanding restricted stock units. (c) This represents the total number of shares remaining available for future issuance under the 2016 Employee Stock Purchase Plan.

28

EXECUTIVE COMPENSATION Set forth below is certain information regarding the historical compensation of our named executive officers during the year ended December 31, 2024 and 2023. Executive Compensation The named executive officers for the year ended December 31, 2024 were: • Deborah Birx, M.D., Chief Executive Officer • Pierre Kyme, Ph.D., Chief Business Officer • David House, Senior Vice President, Finance and Principal Financial Officer • Mina Pastagia, M.D., Former Chief Medical Officer • Richard Rychlik, Former Vice President, Corporate Controller Summary Compensation Table The following table provides information regarding the compensation paid during the last two fiscal years to the named executive officers.

| Name and Principal Position                                                   | ​ | ​ | Year |   |      |   | ​ | ​ | Salary($) |   |         |   | ​ | ​ | Bonus($) |   |        |   | ​ | ​ | StockAwards($)(1) |   |         |   | ​ | ​ | OptionAwards($)(2) |   |         |   | ​ | ​ | Non-EquityIncentive PlanCompensation($) |   |   |   | ​ | ​ | All OtherCompensation($)(7) |   |         |   | ​ | ​ |  Total($) |   |           |   | ​ |
| Deborah Birx, M.D.Chief Executive Officer